A Patented Revolution for the Safe Treatment of Life Threatening Peanut Allergy
Welcome to Natafproseed Ltd., where we are dedicated to developing a groundbreaking treatment for life-threatening peanut allergies. Join us in our mission to provide a safer and more effective solution for allergy sufferers.
Join Our Journey
Transforming Lives Through a Proven Peanut Allergy Treatment
Imagine a world where a child can go to school without fear, where parents no longer live in constant anxiety, and where millions who suffer from life-threatening peanut allergies can finally breathe free. That world is within reach—and we’ve built the solution to get there.
​
Every three minutes, a food allergy reaction sends someone to the emergency room. Among these, peanut allergy is the most common—and the most dangerous. For millions worldwide, a single bite can mean a race against time.
But it doesn’t have to be this way.
​
Our solution is not just a hope—it's a proven, scalable treatment that’s already changing lives. We've developed a scientifically-backed, clinically-tested approach that retrains the immune system to tolerate peanuts, dramatically reducing the risk of severe reactions.
This isn't a temporary fix—it's a long-term transformation for individuals and families trapped by this invisible threat.
Our Vision
Freedom from food allergies—starting with peanuts, expanding to tree nuts. Safe. Natural. Life-changing.
The Global Food Allergy Epidemic
A Silent, Growing Public Health Crisis Affecting Millions
Global Impact
-
250–300 million people worldwide suffer from food allergies
-
Affects up to 10% of children and 4–6% of adults globally
-
1 in 13 U.S. children | 17M+ in Europe | Rapid rise across Asia and LMICs
Rising Danger.
-
Prevalence has doubled in 10–15 years.
-
200,000+ ER visits annually in the U.S. alone.
-
Every 3 minutes, someone is rushed to the ER due to food allergy.
-
Severe, life-threatening reactions (anaphylaxis) are increasing globally.
The Hidden Burden.
-
$25B+ in annual costs in the U.S. (healthcare, food, lost productivity).
-
Emotional and social toll: anxiety, isolation, lifestyle restrictions.
-
Schools, caregivers, and communities under constant strain.
​
Peanut Allergy: A Leading Threat
-
Most common cause of fatal allergic reactions
-
Affects 6M+ Americans, including 1.5M+ children in Europe
-
No cure; lifelong condition in most cases
-
Trace exposure can cause severe or fatal reactions
​
​​
Our Technology
1
The Development of the Mona Peanut
Introducing "The Mona Peanut," our newly developed non-GMO peanut variety, specially designed for Oral Immuno-Therapy (OIT). This innovative peanut offers a tailored solution to enhance treatment efficacy and improve patient outcomes. With its unique properties, The Mona Peanut represents the basis of a significant advancement in allergy treatment.
2
Special Formulation
We have meticulously formulated The Mona Peanut to harness its advantages and uniqueness. Our focus is on maximizing the benefits of this groundbreaking variety for effective allergy management. This careful formulation stage enhances the properties of the Mona Peanut to allow patients receive the best possible support in their treatment journey.
3
Secondary Formulation
We further formulate The Mona Peanut into a child-friendly and effective option to enhance the final Oral Immuno-Therapy treatment in different forms such as in the current form of a biscuit. This innovative proprietary technology also makes it easier for children to engage with their treatment. Our goal is to ensure that the allergy treatment is both effective, safe and accessible for young patients. We are committed to advancing treatment options with The Mona Peanut.
Revolutionizing Allergy Treatment
Our Innovative Approach
​
Our Breakthrough Technology for Peanut and Tree Nut Desensitization:
​
At the forefront of allergy science, our team has pioneered a groundbreaking, non-GMO therapeutic technology that offers real hope to millions living with life-threatening peanut and tree nut allergies.
Leveraging advanced agricultural innovation and proprietary food science, we have developed a unique, non-GMO peanut variety formulated through a special, patented and proprietary process that allows safe, gradual desensitization to peanut proteins.
​
This innovation has already demonstrated exceptional success in clinical trials, where young children previously highly allergic to peanuts were able—after completing our structured treatment protocol—to safely consume normal dietary amounts of peanut-containing foods.
​
Many participants achieved tolerance levels equivalent to multiple whole peanuts, marking a dramatic transformation in both medical safety and quality of life.
​
Our approach doesn’t stop with peanuts. Thanks to the versatility of our technological platform, we are extending this revolutionary technology to other major allergens, including almonds, cashews, and walnuts.
This means that families around the world may soon have access to safe, effective, and lasting relief from some of the most common and dangerous food allergies.
​
By combining proven clinical efficacy, natural non-GMO ingredients, and a patient-friendly, food-based delivery method, our solution empowers patients—not only to survive with their allergies, but to thrive without them.
We are not just treating allergies—we are redefining what's possible for millions of lives around the globe.
Clinical Trials
Exceptional Phase IIa Trial Results for Peanut Allergy Desensitization Protocol Using Mona Peanut Formulations
In a Phase IIa clinical trial evaluating the safety and efficacy of a novel 40-week oral immunotherapy protocol utilizing Mona peanut formulations (administered in cookies, pancakes, and spreads), 33 pediatric patients with confirmed peanut allergies were enrolled.
Of these, 73% were male, and 55% were under the age of 4, representing a high-risk early-age cohort.
At baseline, all participants exhibited a Single Highest Tolerated Dose (SHTD) of less than 100 mg of peanut protein.
Despite this low threshold, 32 of the 33 participants (97%) successfully completed the 40-week desensitization protocol, demonstrating strong adherence and protocol tolerability.
​
At the 6-month post-treatment follow-up, the cohort showed marked desensitization, with the mean tolerated dose increasing to 9.5 grams of peanut protein—a clinically meaningful improvement. This level of tolerance corresponds to the amount found in a standard peanut-containing serving, effectively enabling the majority of participants to safely incorporate age-appropriate peanut-containing foods into their regular diets.
​
These results highlight the potential of Mona peanut-based oral immunotherapy to achieve robust and sustained desensitization in a young pediatric population with severe peanut allergy. The findings support further development in later-stage clinical trials and represent a promising advancement toward practical, dietary-based desensitization strategies.
Meet the Team
Our mission is to commercialize our groundbreaking technology and obtain FDA approval. To ensure the success of this endeavor, our team is comprised of multidisciplinary seasoned professionals each bringing their expertise to the table. Together, we are committed to achieving our goals and allowing for those suffering from life threatening peanut to return to normal life.
Get in Touch
This innovative work has the potential to save lives and improve the quality of life for millions of children and adults worldwide.
Please Get in Touch, If you so wish and believe in our mission and wish to support our efforts, your contribution will help accelerate research, testing, and development.
* Please note: Natafproseed Ltd. is a private company. Contributions are not tax-deductible and do not provide financial returns. All funds will be used solely to advance our research and product development.
​
​